Menopause News and Research

RSS

Menopause is the time in a woman's life when her period stops. It usually occurs naturally, most often after age 45. Menopause happens because the woman's ovary stops producing the hormones estrogen and progesterone.

Informing young women surviving breast cancer about opportunities to have children

At a time when more and more young women are surviving breast cancer and delaying childbirth, it is important to take their needs and wishes about their future fertility into consideration when deciding on treatment, the seventh European Breast Cancer Conference (EBCC7) in Barcelona will hear today.

26 Mar 2010

Fertility remains a significant issue for majority of breast cancer patients

The use of chemotherapy and hormonal treatments in young women can have significant implications for their fertility.

24 Mar 2010

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.

23 Mar 2010

Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine

Pevion Biotech, the Swiss vaccine company, today announced that PEV7, the first vaccine for chronic recurrent thrush - recurrent vulvovaginal candidiasis has entered Phase 1 clinical trial.

22 Mar 2010

Bionovo granted additional grace period for regaining compliance with NASDAQ's minimum bid requirement

Bionovo, Inc. today announced that on March 16, 2010, the Company received a letter from NASDAQ stating that the Company has been granted an additional 180 day grace period, until September 13, 2010, to regain compliance with the minimum bid price of $1.00 required for continued listing on the NASDAQ Capital Market.

19 Mar 2010

New heart-healthy omega-3 crops on horizon

A new heart-healthy, essential omega-3 fatty acid is about to improve an American pantry staple: soybean oil. The new scientific advance will move biotechnology onto the average consumer's daily radar.

17 Mar 2010

Long-term tobacco dependence may affect memory and thinking in women

Men and women with a history of alcohol abuse may not see long-term negative effects on their memory and thinking, but female smokers do, a new study suggests.

16 Mar 2010

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

BioSante Pharmaceuticals, Inc. today announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of pancreatic cancer.

15 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).

11 Mar 2010

Great Point and Deerfield invest in BioSante Pharmaceuticals

BioSante Pharmaceuticals, Inc. today announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.4 million shares of BioSante’s common stock and warrants to purchase up to approximately 5.2 million shares of its common stock, resulting in gross cash proceeds to BioSante of $18 million.

11 Mar 2010

Gamma Pharmaceuticals, Jugular form new joint venture company

Gamma Pharmaceuticals, Inc. announced the formation of a joint venture company with Jugular, Inc., replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.

11 Mar 2010

WebMD Health Exchange platform launched to help consumers get health and wellness support

WebMD Health Corp., the leading source of health information, today announced the launch of WebMD Health Exchange, a new health social networking platform that provides a unique way for consumers to get health and wellness support from the world's largest community of online health-informed consumers.

10 Mar 2010

Rush University Medical Center develops WISHFIT program to help pre-menopausal women reduce visceral fat

Under a $7.1 million grant from the National Institutes of Health, Rush University Medical Center is developing a novel program, called WISHFIT, to help pre-menopausal women reduce visceral fat through a sustained increase in physical activity and reduction in stress.

9 Mar 2010

BioSante Pharmaceuticals enters into securities purchase agreements with Great Point and Deerfield Management

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from two institutional investors to purchase $18 million of securities in a registered direct offering. The investors are Great Point Partners, LLC and Deerfield Management Company. BioSante expects to receive net proceeds of approximately $17.5 million after deducting placement agent fees and other offering expenses.

4 Mar 2010

Pharmacists could be integral to the education and screening of people for osteoporosis, says researcher

University of Alberta researcher Nese Yuksel says pharmacists could be integral to the education and screening of people for osteoporosis, as pharmacists are easily accessible and are playing a greater role in health promotion and disease prevention.

4 Mar 2010

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM").

3 Mar 2010

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company’s Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.

2 Mar 2010

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,632,059, covers methods for manufacturing recombinant antibodies.

2 Mar 2010

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Marking a shift in decades of thought on the cause of osteoporosis, researchers at the University of Arkansas for Medical Sciences have identified an age-related mechanism - not a decrease of the hormone estrogen - as the primary culprit.

27 Feb 2010

Menopause News and Research

Further Reading

Informing young women surviving breast cancer about opportunities to have children

Fertility remains a significant issue for majority of breast cancer patients

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine

Bionovo granted additional grace period for regaining compliance with NASDAQ's minimum bid requirement

New heart-healthy omega-3 crops on horizon

Long-term tobacco dependence may affect memory and thinking in women

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

Great Point and Deerfield invest in BioSante Pharmaceuticals

Gamma Pharmaceuticals, Jugular form new joint venture company

WebMD Health Exchange platform launched to help consumers get health and wellness support

Rush University Medical Center develops WISHFIT program to help pre-menopausal women reduce visceral fat

BioSante Pharmaceuticals enters into securities purchase agreements with Great Point and Deerfield Management

Pharmacists could be integral to the education and screening of people for osteoporosis, says researcher

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News